Anti-Cancer Therapy Methods Using Autophagy Induction via DBI Inhibition
Summary
USPTO published patent application US20260108602A1 covering methods and systems for improving anti-cancer therapies through autophagy induction via inhibition of extracellular diazepam binding inhibitor (DBI). Inventors include Mark de Boer, Guido Kroemer, Léa Montegut, Isabelle Martins, Hui Pan, Hui Chen, and Sijing Li, with application number 19361314 filed October 17, 2025. The application claims therapeutic compositions, methods, and regimens for cancer treatment, including chemo- and immunotherapies.
“The present disclosure provides improved methods, compositions, agents, therapeutic regimens, and systems for cancer treatment, such as improving the outcome of chemo- and/or immunotherapies, and/or inducing autophagy in subjects through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108602A1, establishing a new intellectual property filing covering methods and systems for improving anti-cancer therapies through autophagy induction by inhibiting extracellular DBI. The application claims compositions, therapeutic regimens, and systems for cancer treatment including chemo- and immunotherapies.\n\nCompetitors in the anti-cancer therapeutics space should review freedom-to-operate implications. The published claims may affect ongoing research programs and development strategies in the autophagy modulation and cancer immunotherapy areas.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES
Application US20260108602A1 Kind: A1 Apr 23, 2026
Inventors
Mark DE BOER, Guido KROEMER, Léa MONTEGUT, Isabelle MARTINS, Hui PAN, Hui CHEN, Sijing LI
Abstract
The present disclosure provides improved methods, compositions, agents, therapeutic regimens, and systems for cancer treatment, such as improving the outcome of chemo- and/or immunotherapies, and/or inducing autophagy in subjects through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods.
CPC Classifications
A61K 39/3955 A61K 31/282 A61K 31/573 A61P 35/00 A61K 2039/507
Filing Date
2025-10-17
Application No.
19361314
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.